Supplementary Figures 1 through 4 from Impact of Short-term 1,25-Dihydroxyvitamin D3 on the Chemopreventive Efficacy of Erlotinib against Oral Cancer

Supplementary Fig. S1. MRI of 4NQO-induced tumor growth. Supplementary Fig. S2. MRI-based assessment of response to 1,25(OH)2D3 alone and in combination with erlotinib in the 4NQO model. Supplementary Fig. S3. Ex vivo assessment of response to combination treatment in the 4NQO model. Supplementary Fig. S4. Histopathologic assessment of response to combination treatment in the 4NQO model.